novoGI is committed to advancing patient care by providing an expanding range of comprehensive solutions for GI disease management. The leadership team is strong and cohesive, bringing to the company deep industry knowledge and multidisciplined expertise. novoGI US headquarters are in Atlanta, Georgia; research, development and manufacturing facilities in Netanya, Israel; and its European headquarters are located near Paris, France.
novoGI's nitinol-based compression anastomosis device was recently showcased at ASCRS 2012. Over 10,000 cases have been performed using novoGI’s clinically proven proprietary technology. With more than 50 peer-reviewed publications, evidence substantiates clinical results for ease of use, healing processes, and successful outcomes in regard to leak rates. According to data presented at ASCRS 2012, the company’s clinically proven compression anastomosis device is especially effective in lower anterior resection (LAR) procedures with leak rates ranging from 1.9% to 4%, enabling natural healing of the intestine.